If we have a large budget cut to the FDA in next year's budget, is that going to help or hurt our ability to expedite the drug approval process?
Editor's note · Context
DeGette questions the impact of budget cuts on FDA drug approval efficiency.
Share & report
More from Diana DeGette
Today, the Subcommittee continues to focus on its top priority: aggressively exploring how to bring the COVID-19 pandemic to an end.
I agree with that, but wouldn't you love to see an economy where we could both reduce those environmental impacts on low-income communities and also have low energy prices?
That all should make us want to redouble our efforts here to move away from 20th century energy sources to the energy sources of the future, and the U.S. needs to lead here, not China.
Coming out of the pandemic, we have an opportunity to save lives by bolstering Federal resources that support community mental health and substance use services.





